• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

影像生物标志物研究中的事件发生时间终点

Time-to-Event Endpoints in Imaging Biomarker Studies.

作者信息

Chen Ruizhe, Wang Hao

机构信息

The Sidney Kimmel Comprehensive Cancer Center, Division of Quantitative Sciences, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

出版信息

J Magn Reson Imaging. 2025 Feb;61(2):561-567. doi: 10.1002/jmri.29446. Epub 2024 May 13.

DOI:10.1002/jmri.29446
PMID:38739014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706316/
Abstract

Time-to-event endpoints are widely used as measures of patients' well-being and indicators of prognosis. In imaging-based biomarker studies, there are increasingly more studies that focus on examining imaging biomarkers' prognostic or predictive utilities on those endpoints, whether in a trial or an observational study setting. In this educational review article, we briefly introduce some basic concepts of time-to-event endpoints and point out potential pitfalls in the context of imaging biomarker research in hope of improving radiologists' understanding of related subjects. Besides, we have included some review and discussions on the benefits of using time-to-event endpoints and considerations on selecting overall survival or progression-free survival for primary analysis. LEVEL OF EVIDENCE: 5 TECHNICAL EFFICACY: Stage 3.

摘要

事件发生时间终点广泛用作衡量患者健康状况的指标和预后指标。在基于影像学的生物标志物研究中，越来越多的研究聚焦于在试验或观察性研究环境中，检验影像学生物标志物在这些终点方面的预后或预测效用。在这篇教育性综述文章中，我们简要介绍事件发生时间终点的一些基本概念，并指出在影像学生物标志物研究背景下的潜在陷阱，以期提高放射科医生对相关主题的理解。此外，我们还纳入了一些关于使用事件发生时间终点的益处的综述和讨论，以及关于选择总生存期或无进展生存期进行主要分析的考量。证据级别：5 技术效能：3级

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/b294a7dadf12/JMRI-61-561-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/120b6756f547/JMRI-61-561-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/16a84b997256/JMRI-61-561-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/06af9e196831/JMRI-61-561-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/b294a7dadf12/JMRI-61-561-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/120b6756f547/JMRI-61-561-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/16a84b997256/JMRI-61-561-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/06af9e196831/JMRI-61-561-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c4/11706316/b294a7dadf12/JMRI-61-561-g004.jpg

相似文献

1
Time-to-Event Endpoints in Imaging Biomarker Studies.影像生物标志物研究中的事件发生时间终点
J Magn Reson Imaging. 2025 Feb;61(2):561-567. doi: 10.1002/jmri.29446. Epub 2024 May 13.
2
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险：预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint.临床试验设计中以无事件生存作为主要疗效终点的统计学考虑。
Pharm Stat. 2021 Jul;20(4):721-736. doi: 10.1002/pst.2103. Epub 2021 Feb 16.
5
An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.对用于评估由一个或多个感兴趣事件组成的事件发生时间替代终点的两阶段元分析Copula建模方法的研究。
Pharm Stat. 2017 Sep;16(5):322-333. doi: 10.1002/pst.1812. Epub 2017 May 19.
6
Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials.眼科临床试验中影像生物标志物使用的十年概况
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO76-BIO81. doi: 10.1167/iovs.17-21790.
7
Statistical considerations for the next generation of clinical trials.下一代临床试验的统计学考虑。
Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014.
8
Phase II cancer clinical trials for biomarker-guided treatments.用于生物标志物引导治疗的癌症II期临床试验。
J Biopharm Stat. 2018;28(2):256-263. doi: 10.1080/10543406.2017.1372777. Epub 2017 Nov 27.
9
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.轻链型和转甲状腺素蛋白淀粉样变临床试验影像终点的发展：淀粉样变论坛会议记录
JACC Cardiovasc Imaging. 2025 May;18(5):602-617. doi: 10.1016/j.jcmg.2024.11.003. Epub 2025 Feb 21.
10
Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review.嵌合抗原受体T细胞（CAR T）临床试验中事件发生时间终点的报告与定义不一致：一项综述
Transplant Cell Ther. 2025 Apr;31(4):271.e1-271.e13. doi: 10.1016/j.jtct.2024.11.012. Epub 2024 Nov 26.

本文引用的文献

1
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.无进展生存期不应作为抗癌药物注册的主要终点。
J Clin Oncol. 2023 Nov 10;41(32):4968-4972. doi: 10.1200/JCO.23.01423. Epub 2023 Sep 21.
2
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.监管挑战：替代终点而非总生存期是否足以用于（新）辅助癌症治疗的监管批准？瑞士药品监管局的观点。
J Clin Oncol. 2023 Nov 10;41(32):4973-4975. doi: 10.1200/JCO.23.01442. Epub 2023 Sep 21.
3
A Cox Nomogram for Assessing Recurrence Free Survival in Hepatocellular Carcinoma Following Surgical Resection Using Dynamic Contrast-Enhanced MRI Radiomics.
基于动态对比增强 MRI 放射组学的 Cox 列线图预测肝细胞癌术后无复发生存。
J Magn Reson Imaging. 2023 Dec;58(6):1930-1941. doi: 10.1002/jmri.28725. Epub 2023 May 13.
4
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.不可调和的差异：缓解率、无进展生存期和总生存期之间的脱节
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
5
Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure.在适合移植的肾衰竭患者中，与长期透析相比，首次单器官已故供体肾移植在各年龄段的生存获益。
JAMA Netw Open. 2022 Oct 3;5(10):e2234971. doi: 10.1001/jamanetworkopen.2022.34971.
6
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments.血液恶性肿瘤中无事件生存作为替代终点的有效性：文献回顾和卫生技术评估。
Crit Rev Oncol Hematol. 2022 Jul;175:103711. doi: 10.1016/j.critrevonc.2022.103711. Epub 2022 May 16.
7
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.血液系统恶性肿瘤中PI3K抑制剂的传奇故事：生存是最终的安全性终点。
Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.
8
Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy.基于多参数 MRI 的放射组学特征模型预测肝内胆管细胞癌患者行肝部分切除术后的总生存情况
J Magn Reson Imaging. 2022 Sep;56(3):739-751. doi: 10.1002/jmri.28071. Epub 2022 Jan 20.
9
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.来那度胺耐药的多发性骨髓瘤患者使用美法仑或泊马度胺联合地塞米松治疗（OCEAN）：一项随机、头对头、开放标签、3 期研究。
Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12.
10
Differential frequency in imaging-based outcome measurement: Bias in real-world oncology comparative-effectiveness studies.基于影像学的结局测量中的频率差异：真实世界肿瘤学比较有效性研究中的偏倚。
Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):46-54. doi: 10.1002/pds.5323. Epub 2021 Jul 21.